S. Deenadayalan

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial

J. Rosenstock, M. Davies, H. Watada, 2019, JAMA.

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A subgroup analysis by baseline variables in the PIONEER 9 and PIONEER 10 trials

H. Kaneto, Yuichiro Yamada, Y. Terauchi, 2022, Journal of diabetes investigation.

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial.

H. Kaneto, D. Yabe, N. Inagaki, 2020, The lancet. Diabetes & endocrinology.

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.

Yuichiro Yamada, H. Katagiri, Y. Seino, 2020, The lancet. Diabetes & endocrinology.

Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials

Y. Terauchi, T. Kadowaki, H. Watada, 2021, Diabetes, obesity & metabolism.

Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial

T. Danne, B. Bode, V. Iotova, 2019, Diabetes Care.

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

F. Knop, J. Frias, I. Lingvay, 2023, The Lancet.